Both in 1995 and 1996 we will have seen and will see the introduction of new cytotoxic and other agents to treat the most common cancers like lung, colon and breast. Taxoids, antimetabolites, topoisomerase I inhibitors have new mechanisms of action and seem to provide hitherto unexpected therapeutic gains. Only a wider experience will tell the exact role these agents have to play, and will show if their price is indeed justified by an advantage ta the patient, as it would seem at a first glance.
|Translated title of the contribution||Medical oncology|
|Number of pages||3|
|Journal||Medecine et Hygiene|
|Publication status||Published - Jan 10 1996|
ASJC Scopus subject areas